Work

Abstract PO3-18-11: A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer

Year: 2024

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs23-po3-18-11

Authors: Ciara O'Sullivan, Karla Ballman, Linda McCall, Tyler Zemla, Anna Weiss, Melissa Mitchell, Victoria Blinder, Nadine Tung, William Irvin, Myounghee Lee, Sailaja Kamaraju, Matthew Goetz, W. Fraser Symmans, Virginia Borges, Ian Krop, Ann Partridge, Lisa Carey

Institutions: Mayo Clinic, Weill Cornell Medicine, Duke University, University of Rochester Medicine, University of Rochester, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Beth Israel Deaconess Medical Center, University of Maryland Medical Center, Medical College of Wisconsin, University of Colorado Anschutz, Yale Cancer Center, Yale University, Dana-Farber Cancer Institute, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4396587396

Cites:

Cited by:

Related to: 10